This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

7 Sep 2023 Ibex Launches Galen™ Breast HER2, Supporting Improved Biomarker Scoring in Breast Cancer Patients
Read more
6 Sep 2023 Ibex Raises $55 Million in Series C Funding to Drive Global Adoption of AI for Cancer Diagnosis
Read more
9 Mar 2023 Ibex and Alverno Laboratories sign multi-year, multi-tissue expansion agreement of AI for cancer diagnosis
Read more
7 Mar 2023 Ibex secures PathLAKE contracts to roll out AI-based cancer diagnostics to UK hospitals
Read more
6 Mar 2023 Ibex scoops second win of the UK Artificial Intelligence Award with leading NHS trusts
Read more
9 Feb 2023 Ibex’s Galen™ Prostate becomes first standalone AI-powered cancer diagnostics solution to obtain CE mark under the IVDR
Read more
24 Jan 2023 Ibex Medical Analytics Enters Collaboration with AstraZeneca and Daiichi Sankyo to Develop AI-based HER2 Scoring Product
Read more
21 Dec 2022 Institut Curie study published in a Nature Journal reporting excellent outcomes of Ibex’s AI solution for breast cancer detection
Read more
7 Dec 2022 Leading UK diagnostics provider source LDPath expands AI capabilities with Ibex Medical Analytics
Read more
4 Sep 2022 Ibex announces Galen™ 3.0, a transformative cancer diagnostics platform offering new detection capabilities and a broad feature set
Read more